Print

Rhein Biotech Release: Pre-clinical Results For CMV Vaccine Candidate Look Promising  
12/14/2005 1:10:40 PM

Hannover / Düsseldorf, 13th December 2005 - Vakzine Projekt Management GmbH (VPM) has decided to extend its cooperation with the vaccine development specialist Rhein Biotech GmbH. VPM’s in-licensed vaccine candidate for the prevention of infection with cytomegalovirus (CMV) underwent successful pre-clinical trials this year as part of a feasibility study at Rhein Biotech. Within the new development contract Rhein Biotech is responsible for all aspects of process development, scale-up and the production of clinical trial material.